First Wave BioPharma Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19
28 mars 2022 16h23 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference
22 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference
08 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
03 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Closing of $9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
02 mars 2022 17h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer
01 mars 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
28 févr. 2022 08h01 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted,...
First Wave BioPharma to Participate in the 2022 BIO CEO & Investor Conference
07 févr. 2022 07h30 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
13 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by...
First Wave BioPharma Announces Further Adjournment of Annual Meeting
07 janv. 2022 09h16 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...